Evidence map›Paper›PMID 36822701›Full record

ReviewObstetrics and gynecology clinics of North America2023

COVID-19 Therapeutics and Considerations for Pregnancy.

Naima T Joseph, Ai-Ris Y Collier

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Obstetrics and gynecology clinics of North America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. COVID-19 Antiviral Medication Use Among Pregnant and Recently Pregnant US Outpatients.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Naima T JosephDivision of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Kirstein 3rd Floor, Boston, MA 02215, USA; Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, MA, USA. Electronic address: Njoseph5@bidmc.harvard.edu.
Ai-Ris Y CollierDivision of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Kirstein 3rd Floor, Boston, MA 02215, USA; Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, MA, USA.

Funding

Defining the optimal type and timing of COVID-19 vaccine in pregnancyR21AI169309 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI COLLIER, AI-RIS YONEKURA · 2022 to 2023
$475k
NIAID NIH HHS R21 AI169309
6 · The paper itself

Abstract

The COVID-19 pandemic has generated an unprecedented amount of novel and repurposed vaccines and therapeutics that have been rapidly developed and implemented into clinical use. Unfortunately, pregnant persons have been excluded from most phase III clinical studies; therefore, our understanding regarding their safety for use in this population stems from understanding of theoretic risks and observational data. In this review, the authors discuss pregnancy-specific considerations for COVID-19 therapeutics.

Indexed as

COVID-19FemaleHumansPandemicsPregnancyCOVID-19PregnancyTherapeuticsVaccines

Identifiers

PMID36822701
PMCPMC9584862

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.